New study aims to make HIV prevention easier for black women

NCT ID NCT05514509

Completed Prevention Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 4 study looked at how to best offer cabotegravir PrEP (a long-acting injection and tablets) to Black cisgender and transgender women in the US who do not have HIV. About 370 women took part, and researchers measured how well different delivery strategies worked in real clinics. The goal was to find ways to make HIV prevention more accessible and acceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabotegravir (injection and tablet)
What this could lead to: If successful, this study could show that offering cabotegravir PrEP in different ways helps more Black women at risk of HIV get and stay on prevention.
What could go wrong: This is a completed implementation study, not a test of whether the drug works. The results may not apply to all settings or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Washington D.C., District of Columbia, 20005, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20010, United States
GSK Investigational Site

Washington D.C., District of Columbia, 20017, United States
GSK Investigational Site

Miami, Florida, 33137, United States
GSK Investigational Site

Orlando, Florida, 32808, United States
GSK Investigational Site

Tampa, Florida, 33611, United States
GSK Investigational Site

West Palm Beach, Florida, 33401, United States
GSK Investigational Site

Atlanta, Georgia, 30303, United States
GSK Investigational Site

Atlanta, Georgia, 30309, United States
GSK Investigational Site

Atlanta, Georgia, 30312, United States
GSK Investigational Site

Bridgeport, Kansas, 06605, United States
GSK Investigational Site

Detroit, Michigan, 48201, United States
GSK Investigational Site

Las Vegas, Nevada, 89104, United States
GSK Investigational Site

Brooklyn, New York, 10001, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19114, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19147, United States
GSK Investigational Site

Memphis, Tennessee, 38104, United States
GSK Investigational Site

Dallas, Texas, 75201, United States
GSK Investigational Site

Houston, Texas, 77006, United States
GSK Investigational Site

Houston, Texas, 77021, United States
GSK Investigational Site

Norfolk, Virginia, 23510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.